Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation

DISEASE CHARACTERISTICS:

• Diagnosis of recurrent or metastatic renal cell carcinoma
• Failed interleukin-2 (IL-2)-based therapy OR intolerant to IL-2
• Clinically evident and followable disease

• Availability of 1 of the following compatible donors:

  • Related HLA-identical or 1-Ag mismatched donor
  • Unrelated HLA-A, B, DRB1-matched donor

PATIENT CHARACTERISTICS:

Age

• Any age

Performance status

• Karnofsky 70-100%

Life expectancy

• No concurrent illness that severely limits life expectancy

Hematopoietic

• Not specified

Hepatic

• No episode of hepatitis within the past month
• No evidence of chronic active hepatitis or cirrhosis

Renal

• Creatinine no greater than 2 mg/dL

Cardiovascular

• LVEF at least 40%
• No uncontrolled arrhythmias
• No symptomatic cardiac disease

Pulmonary

• FEV_1, FVC, and DLCO at least 50% of predicted (unless due to metastatic disease)

Other

• Not pregnant
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 3 months after study participation
• No active infection
• HIV negative

PRIOR CONCURRENT THERAPY:

Biologic therapy

• See Disease Characteristics

Chemotherapy

• Not specified

Endocrine therapy

• Not specified

Radiotherapy

• Not specified

Surgery

• Not specified